CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 190 enrolled
Drug / intervention
MT-8554drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03541200
NCT03541200Phase 2Completed
CompareCT.gov

An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01

Tanabe Pharma America, Inc.·interventional·Posted May 30, 2018·Updated Jan 23, 2026

In Brief

A Phase 2 clinical trial evaluating MT-8554 for Vasomotor Symptoms (VMS). Completed, enrolled 190 participants across 53 sites.

Detailed Summary

An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasomotor Symptoms (VMS)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 30, 2018
Enrollment StartApr 18, 2018
Primary CompletionNov 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.1 years ago

Interventions

MT-8554drug

MT-8554 Oral